| Predominance of the autoimmune response to myelin oligodendrocyte glycoprotein (MOG) in multiple sclerosis: reactivity to the extracellular domain of MOG is directed against … NK De Rosbo, M Hoffman, I Mendel, I Yust, J Kaye, R Bakimer, S Flechter, ... European journal of immunology 27 (11), 3059-3069, 1997 | 221 | 1997 |
| Vaccination for neuroprotection in the mouse optic nerve: implications for optic neuropathies J Fisher, H Levkovitch-Verbin, H Schori, E Yoles, O Butovsky, JF Kaye, ... Journal of Neuroscience 21 (1), 136-142, 2001 | 218 | 2001 |
| Regulation of experimental autoimmune encephalomyelitis by CD4+, CD25+ and CD8+ T cells: analysis using depleting antibodies E Montero, G Nussbaum, JF Kaye, R Perez, A Lage, A Ben-Nun, ... Journal of autoimmunity 23 (1), 1-7, 2004 | 158 | 2004 |
| Laquinimod arrests experimental autoimmune encephalomyelitis by activating the aryl hydrocarbon receptor J Kaye, V Piryatinsky, T Birnberg, T Hingaly, E Raymond, R Kashi, ... Proceedings of the National Academy of Sciences 113 (41), E6145-E6152, 2016 | 123 | 2016 |
| Treatment of Crohn's disease with laquinimod N Tarcic, A Haviv, E Blaugrund, J Kaye US Patent 8,598,203, 2013 | 104 | 2013 |
| The myelin-associated oligodendrocytic basic protein region MOBP15–36 encompasses the immunodominant major encephalitogenic epitope (s) for SJL/J mice and predicted epitope (s … NK De Rosbo, JF Kaye, M Eisenstein, I Mendel, R Hoeftberger, ... The Journal of Immunology 173 (2), 1426-1435, 2004 | 76 | 2004 |
| Rhesus monkeys are highly susceptible to experimental autoimmune encephalomyelitis induced by myelin oligodendrocyte glycoprotein: characterisation of immunodominant T-and B … NK de Rosbo, HPM Brok, J Bauer, JF Kaye, B A’t Hart, A Ben-Nun Journal of neuroimmunology 110 (1-2), 83-96, 2000 | 69 | 2000 |
| Anatomy of T cell autoimmunity to myelin oligodendrocyte glycoprotein (MOG): Prime role of MOG44F in selection and control of MOG‐reactive T cells in H‐2b mice A Ben‐Nun, NK de Rosbo, N Kaushansky, M Eisenstein, L Cohen, ... European journal of immunology 36 (2), 478-493, 2006 | 49 | 2006 |
| The central nervous sytem-specific myelin oligodendrocytic basic protein (MOBP) is encephalitogenic and a potential target antigen in multiple sclerosis (MS) JF Kaye, NK de Rosbo, I Mendel, S Flechter, M Hoffman, I Yust, ... Journal of Neuroimmunology 102 (2), 189-198, 2000 | 49 | 2000 |
| Kerlero de Rosbo JF Kaye N., Mendel, I., Flechter, S., Hoffman, M., Yust, I., Ben-Nun, A, 189-198, 2000 | 48 | 2000 |
| Mice overexpressing Bcl-2 in their neurons are resistant to myelin oligodendrocyte glycoprotein (MOG)-induced experimental autoimmune encephalomyelitis (EAE) D Offen, JF Kaye, O Bernard, D Merims, CI Coire, H Panet, E Melamed, ... Journal of Molecular Neuroscience 15, 167-176, 2000 | 37 | 2000 |
| Impact of glatiramer acetate on B cell-mediated pathogenesis of multiple sclerosis S Kuerten, LJ Jackson, J Kaye, TL Vollmer CNS drugs 32 (11), 1039-1051, 2018 | 33 | 2018 |
| Aryl hydrocarbon receptor activation in astrocytes by laquinimod ameliorates autoimmune inflammation in the CNS V Rothhammer, JE Kenison, Z Li, E Tjon, MC Takenaka, CC Chao, ... Neurology: Neuroimmunology & Neuroinflammation 8 (2), e946, 2021 | 28 | 2021 |
| Effects of surface finish JT Burwell, J Kaye, DW Van Nymegen, DA Morgan American Society of Mechanical Engineers 8 (2), A49-A58, 1941 | 26 | 1941 |
| Directed evolution of a soluble human IL-17A receptor for the inhibition of psoriasis plaque formation in a mouse model M Zaretsky, R Etzyoni, J Kaye, L Sklair-Tavron, A Aharoni Chemistry & Biology 20 (2), 202-211, 2013 | 25 | 2013 |
| A novel cytidine analog, RX-3117, shows potent efficacy in xenograft models, even in tumors that are resistant to gemcitabine MY Yang, YB Lee, CH Ahn, J Kaye, T Fine, R Kashi, O Ohne, K Smid, ... Anticancer research 34 (12), 6951-6959, 2014 | 22 | 2014 |
| Treatment of multiple sclerosis with combination of laquinimod and dimethyl fumarate JF Kaye US Patent App. 13/800,047, 2013 | 22 | 2013 |
| Treatment of rheumatoid arthritis with a combination of laquinimod and methotrexate J Kaye, E Blaugrund, N Tarcic US Patent 8,501,766, 2013 | 22 | 2013 |
| AL101, a gamma-secretase inhibitor, has potent antitumor activity against adenoid cystic carcinoma with activated NOTCH signaling R Ferrarotto, V Mishra, E Herz, A Yaacov, O Solomon, R Rauch, ... Cell Death & Disease 13 (8), 678, 2022 | 20 | 2022 |
| Laquinimod ameliorates secondary brain inflammation J Nedelcu, C Reinbach, P Riedler, M Brendel, A Rominger, J Kaye, ... Neurobiology of disease 134, 104675, 2020 | 18 | 2020 |
